Patents by Inventor Barbro AGREN

Barbro AGREN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12285468
    Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.
    Type: Grant
    Filed: September 28, 2023
    Date of Patent: April 29, 2025
    Assignee: IPSEN BIOPHARM LIMITED
    Inventors: Anders Jarstad, Anna Friis, Ulf Stahl, Ann Gurell, Barbro Agren, Emilia Edstrom, Andrew Pickett
  • Publication number: 20240050539
    Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.
    Type: Application
    Filed: September 28, 2023
    Publication date: February 15, 2024
    Applicant: IPSEN BIOPHARM LIMITED
    Inventors: Anders JARSTAD, Anna FRIIS, Ulf STAHL, Ann GURELL, Barbro AGREN, Emilia EDSTROM, Andrew PICKETT
  • Publication number: 20230190892
    Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.
    Type: Application
    Filed: June 28, 2021
    Publication date: June 22, 2023
    Applicant: IPSEN BIOPHARM LIMITED
    Inventors: Anders JARSTAD, Anna FRIIS, Ulf STAHL, Ann GURELL, Barbro AGREN, Emilia EDSTROM, Andrew PICKETT
  • Publication number: 20230181702
    Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.
    Type: Application
    Filed: February 24, 2023
    Publication date: June 15, 2023
    Applicant: IPSEN BIOPHARM LIMITED
    Inventors: Anders JARSTAD, Anna FRIIS, Ulf STAHL, Ann GURELL, Barbro AGREN, Emilia EDSTROM, Andrew PICKETT
  • Publication number: 20220160844
    Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.
    Type: Application
    Filed: February 14, 2022
    Publication date: May 26, 2022
    Applicant: Ipsen Biopharm Limited
    Inventors: Anders JARSTAD, Anna Friis, Ulf Stahl, Ann Gurell, Barbro Agren, Emilia Edstrom, Andrew Pickett
  • Publication number: 20210330765
    Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.
    Type: Application
    Filed: June 28, 2021
    Publication date: October 28, 2021
    Applicant: IPSEN BIOPHARM LIMITED
    Inventors: Anders JARSTAD, Anna FRIIS, Ulf STAHL, Ann GURELL, Barbro AGREN, Emilia EDSTROM, Andrew PICKETT
  • Publication number: 20190183988
    Abstract: The invention relates to stable liquid neurotoxin formulations which are free of animal proteins, comprising a surfactant, an amino acid selected from tryptophan and tyrosine, a buffer comprising sodium, chloride and phosphate ions, which have a pH between 5.5 and 8, and which are stable for 2 months. These compositions are suitable for use in therapy and in particular for administration to a patient to achieve a desired therapeutic or aesthetic effect. The invention also relates to the use of an amino acid selected from tryptophan and tyrosine to protect a proteinaceous neurotoxin from degradation in a liquid composition which is free of animal derived proteins.
    Type: Application
    Filed: May 26, 2017
    Publication date: June 20, 2019
    Inventors: Anders JARSTAD, Anna FRIIS, Ulf STAHL, Ann GURELL, Barbro AGREN, Emilia EDSTROM, Andrew PICKETT